CXCR4-directed [68Ga]Ga-PentixaFor PET/CT vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in primary aldosteronism

Stichting Radboud universitair medisch centrum0 个研究点目标入组 228 人开始时间: 2024年7月15日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•The patient has a diagnosis of primary aldosteronism, confirmed by elevated aldosterone/renin ratio (ARR) and intravenous salt-loading test (according to the Endocrine Society guidelines), Patients who fall in the grey area” according to the Endocrine Society guidelines (1), will be discussed with all site investigators before inclusion to reach consensus on the diagnosis before inclusion., Age over 18 years at time of consent, Signed informed consent

•Refusal by the patients to undergo AVS, [68Ga]Ga-PentixaFor PET/CT, CT, or adrenalectomy, Suspicion of familial hyperaldosteronism type 1 (FH-1), type 2 (FH-2), type 3 (FH-3), or type 4 (FH-4), Suspicion of adrenocortical carcinoma, Severe comorbidity potentially interfering with treatment or health-related quality of life, Requirement of medication interfering with the study protocol, Any medical condition present that in the opinion of the investigator will affect patients’ clinical status., Pregnancy or lactation, Estimated glomerular filtration rate (eGFR) < 40 ml/min/1.73m²

发起方

Stichting Radboud universitair medisch centrum